Section Arrow
NTLA.NASDAQ
- Intellia Therapeutics
Quotes are at least 15-min delayed:2025/07/15 22:05 EDT
Regular Hours
Last
 11.48
-0.47 (-3.93%)
Day High 
12.2 
Prev. Close
11.95 
1-M High
12.34 
Volume 
3.45M 
Bid
11.45
Ask
11.6
Day Low
11.305 
Open
12.17 
1-M Low
8.245 
Market Cap 
1.24B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 10.99 
20-SMA 10.15 
50-SMA 9.06 
52-W High 28.18 
52-W Low 5.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.23/-4.23
Enterprise Value
1.43B
Balance Sheet
Book Value Per Share
7.53
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
57.88M
Operating Revenue Per Share
0.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KAPAKairos Pharma Ltd.1.17+0.4849+70.78%-- 
NCNANuCana plc0.0502+0.0043+9.37%-- 
PLRZPolyrizon Ltd1.04+0.3579+52.47%-- 
CYCCCyclacel Pharmaceuticals Inc12.33+9.02+272.51%0.08PE
IOVAIovance Biotherapeutics1.94-0.07-3.48%-- 
Quotes are at least 15-min delayed:2025/07/15 22:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.